Thank you for subscribing - Volition

Thank you for subscribing.

Our mission is to save lives and improve outcomes for millions of people and animals worldwide and we’re grateful for your interest.

We will be in touch with our latest news, webinars and research.

Volition 230619

Further help & information.

In the meantime, why not check explore our resource section, where you’ll find a wealth of helpful information.

Product Resources

Brochure & Clinical Papers

EZH2 inhibition enhances the activity of Carboplatin in aggr…

Poster & Publications

Clinical study establishes Nu.Q® NETs H3.1 as predictor of 2…

Volition Issues Business Review 2024

VolitionRx Appoints LifeSci Advisors as Investor Relations C…

Study shows Nu.Q® Lung Cancer Test differentiated malignant …

VolitionRx Announces Pricing of up to $1.9 Million Registere…

Lung cancer awareness month

VolitionRx Limited Announces Third Quarter 2024 Financial Re…

VolitionRx Limited Schedules Third Quarter 2024 Earnings Con…

Volition Appoints Timothy I. Still as Chairman

Multiple studies show Nu.Q® NETs test could predict sepsis p…

Symposium 2024 report: ‘Sepsis – a brighter hope…

Media & Downloads